GSK plc (NYSE:GSK) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its position in shares of GSK plc (NYSE:GSK) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,348 shares of the pharmaceutical company’s stock after purchasing an additional 1,737 shares during the period. Thrivent Financial for Lutherans’ holdings in GSK were worth $2,181,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GSK. B. Riley Wealth Advisors Inc. lifted its position in shares of GSK by 15.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 48,795 shares of the pharmaceutical company’s stock worth $2,092,000 after purchasing an additional 6,348 shares in the last quarter. Tidal Investments LLC lifted its position in shares of GSK by 6.7% during the first quarter. Tidal Investments LLC now owns 27,335 shares of the pharmaceutical company’s stock worth $1,172,000 after purchasing an additional 1,715 shares in the last quarter. Advisory Resource Group acquired a new position in shares of GSK during the first quarter worth $320,000. Atria Investments Inc lifted its position in shares of GSK by 27.5% during the first quarter. Atria Investments Inc now owns 54,657 shares of the pharmaceutical company’s stock worth $2,343,000 after purchasing an additional 11,804 shares in the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of GSK by 300.5% in the first quarter. Cetera Investment Advisers now owns 281,168 shares of the pharmaceutical company’s stock worth $12,054,000 after buying an additional 210,971 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Barclays upgraded shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $34.32 on Thursday. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $71.13 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 1.31 and a beta of 0.66. The firm has a 50-day moving average of $37.56 and a two-hundred day moving average of $40.13.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.58%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is presently 99.35%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.